Benign Prostatic Hyperplasia News Archive
Low physical activity may increase risk of lower urinary tract symptoms in study of Korean men
A previous study showed that using 5-ARIs to treat benign prostate hyperplasia decreased the risk of low-grade PCa.
Men using allopurinol had a 22% lower risk of a BPH diagnosis.
Decrease in scores on the Men's Sexual Health Questionnaire mostly due to ejaculation disorders.
A novel approach called "Aquablation" provides results comparable to TURP, but with a decreased likelihood of retrograde ejaculation.
Patients who underwent the minimally invasive procedure had a 36%, 50%, and 44% improvement in IPSS, quality of life, and peak flow rate, respectively, at 5 years.
Long-term use of the drug may predispose men to worsening erectile dysfunction and elevated risk of diabetes and non-alcoholic fatty liver disease.
PUL involves placement of small permanent metallic implants into the prostate that lift the lateral lobes away from the urethra and remove obstruction.
NSAID users had a 2-fold increased risk of BPH medication use, 59% increased risk of a recorded BPH diagnosis, and 61% increased risk for BPH surgery.
Average International Prostate Symptom Score remained low 5 years after the PVP laser procedure.
Researchers identified a predictor of new-onset UI after HoLEP that may aid urologists in clinical practice.
In a study, 81.1% of men were able to void after an average of 28 days after treatment.
The laser procedure was successful for 7 selected patients with enlarged prostates and LUTS harboring low-risk prostate cancer.
In a study, 86% of prostatic urethral lift patients experienced symptom relief in the first month.
Findings emerged from an analysis of data from 2588 men who participated in the REDUCE trial.
Study confirms small, but significant increases in the risks of these mental health problems among men taking the medication.
Longer use of finasteride at a dosage of 1.25 mg/day or less among men younger than 42 years is associated with greater risk, study finds.
The finasteride and dutasteride recipients had significantly less mean blood loss than the placebo group.
Benign prostatic hyperplasia is more likely to develop among men with larger waist circumference and body mass index and higher leptin levels.
Poor baseline functional status and having a Foley catheter preoperatively were associated with greater risk of TURP or TULIP failure.
New findings confirm previous reports.
Use of 5ARIs for BPH was associated with a statistically significant increased, pooled relative risk for sexual dysfunction.
Patients' pre-existing urinary problems influenced their perceptions of symptom relief after prostate cancer treatment.
In a meta-analysis, men with benign prostatic hyperplasia had a 2.9 times and 1.7 times increased incidence of prostate cancer and bladder cancer, respectively.
Study documents significant improvements in frequency, urgency, and nocturia.
Patients experienced a sustained decrease in AUA Symptom Score, and 95% of patients report being satisfied or very satisfied with the procedure.
Significant improvements in lower urinary tract symptoms are durable to 24 months, data show.
LUTS is 49% more likely to develop in men with a PSA level above 6 ng/mL versus 4 ng/mL or less.
New data show that the minimally invasive procedure is superior overall to TURP for treating BPH-related lower urinary tract symptoms.
Procedure partially blocks blood flow to the gland and appears to ease the need to urinate.
Three quarters of patients experienced significant improvements in lower urinary tract symptoms and quality of life observed and were satisfied with treatment.
Prostatic arterial embolization significantly reduced volumes of median lobes, central zones, peripheral zones, and whole prostate glands.
Men receiving common medical treatments for LUTS/BPH, including phytotherapy, experienced similar symptom relief.
The risk is 67% higher in men with a prostate size of 40.1-80 mL than those with smaller glands.
The risk of bladder outlet obstruction increased 34% per unit increase in serum PSA and decreased 23% per unit increase in maximal flow rate.
A recent review found little evidence to support severe lower urinary tract symptoms as a contraindication to TRT.
More adverse events seen when people undergoing interventional radiology have negative attitude.
Previous studies may have overlooked the placebo effect.
Use of high-velocity saline streams show promise in a small, first-in-man study.
Review shows significant change in symptom scores, maximum urinary flow in sham surgery arm
Age, obesity promote methylation, suppression of 5-reductase 2
Increasing thickness was associated with increasing number of poor indicators for bladder outlet obstruction in men with enlarged prostates.
CAM associated with polypharmacy, vision impairment, and urologic comorbidities.
The malignancy is 36% less likely to develop, after adjusting for age and smoking, data show.
Symptom improvement was greater in patients receiving tamsulosin plus darifenacin compared with tamsulosin monotherapy.
In a study, only older age and greater total PSA density were independently associated with an increased risk of a PCa diagnosis.
Patients with BPH and mild-to-moderate LUTS can be managed without immediate prostatic surgery, study suggests.
Prostatic urethral lift is minimally invasive and, according to a new study, the procedure's beneficial effects are durable out to 3 years.
Neither drug decreased operative time, prostate volume, or weight of gland resected.
Overall, men with LUTS showed remarkably poor knowledge about their symptoms.
Ten years after the laser procedure, no reoperation was needed for 95% of patients treated for symptomatic benign prostatic hyperplasia.
Men who reported having severe lower urinary tract symptoms (LUTS) had a 64% increased risk of the malignancy compared with those who reported no LUTS.
Outcomes were significantly better in men with large prostates, however.
Depression is prevalent among men with benign prostatic hyperplasia (BPH).
Men with lower levels of sedentary time had a significantly lower risk of benign prostatic hyperplasia (BPH).
Vancouver Symptom Score linked to bullying victimization and perpetrator scores
Metabolic syndrome linked to severity of LUTS; symptoms improve after bariatric surgery
From 2000 to 2011, transurethral resection of the prostate for benign prostatic hyperplasia (BPH) decreased and laser procedures increased.
Sitting to urinate is associated with an improved urodynamic profile in lower urinary tract symptoms (LUTS).
Many urologists not uniformly adhering to AUA guidelines for the management of benign prostatic hyperplasia/lower urinary tract symptoms.
Men with diabetic peripheral neuropathy have an increased occurrence of erectile dysfunction and lower-urinary-tract symptoms.
Only 10% of men aged 45-69 years who progress from no or mild to moderate or severe lower urinary tract symptoms are treated, study finds.
Lack of efficacy is the main reason for the switch.
Compared with standing, sitting was associated with significantly lower post-void residual volume.
Following surgery, improvement in sexual satisfaction correlated with improvements in all lower urinary tract symptoms.
This rate of incidental PCa detection is lower than found in previous studies.
Researchers compared transurethral resection of the prostate with prostate artery embolization in a randomized trial.
Ejaculatory function worsens, however, in men taking 5 alpha-reductase inhibitors.
Using leave-one-out cross-validation, sensitivity of 78 percent and specificity of 67 percent.
Alpha blockers and 5-alpha reductase inhibitors increase the risk of ejaculatory dysfunction, a systematic review and meta-analysis shows.
Range of risk factors identified for incidence and remission of ED, dyadic and solitary sexual desire.
New study also suggests that low preoperative hematocrit and albumin levels predict adverse outcomes.
Cumulative rates of clinical success were 87.2% at 3 months, 80.2% at 18 months, and 72.3% at 36 months (long term).
Older and obese men and those with low HDL cholesterol are more likely to have the syndrome as a determinant of prostatic enlargement.
About 30 percent of men experience an AUA symptoms index improvement of 3 or more points.
Early results from a small group of patients show a clinical success rate of 95%.
The FDA has approved the first permanent implant to relieve low or blocked urine flow in men aged 50 years and older with BPH.
Improvements observed in urinary symptoms and bone mineral density.
Men with a body mass index of 30 kg/m2 or higher had a 39.3% prevalence of low testosterone, study finds.
Significant declines in International Prostate Symptom Score observed, regardless of whether or not men lost weight or used a phosphodiesterase-5 inhibitor.
Desmopressin appears to reduce nocturia and other LUTS while also significantly increasing testosterone levels in late-onset hypogonadism.
Adding ketoconazole to tamsulosin increased the likelihood of a successful trial without catheter in men with benign prostatic obstruction.
Study results underscore the need for additional research to find other surrogate markers of urinary infection.
Lower urinary tract symptoms actually improved in many men, with minimal change in PSA level.
Lower urinary tract symptoms (LUTS) are commonly attributed to benign prostatic hyperplasia.
BPH has long been thought to be an inevitable function of genetic predisposition and age related changes in sex steroid hormones.
Saw palmetto remains the most common herbal treatment for men with LUTS.
Orange or grapefruit juice consumption may be protective in men, study finds.
Highest intake was associated with a 46% decreased progression risk compared with the lowest intake.
The incidence of emergency department visits rose 36% from 2007 to 2010 in California.
Many men even experience an improvement in lower urinary tract symptoms.
Tadalafil plus finasteride improved symptoms scores better than finasteride plus placebo.
Lower urinary tract symptoms alone should raise suspicion for the malignancy.
Following surgery, symptom severity declined significantly and remained stable over 10 years.
Alpha blockers are the mostly commonly prescribed drugs to treat LUTS secondary to BPH.
If patients are not bothered by symptoms, they do not necessarily require treatment, Australian researcher says.
No evidence of toxicity for patients given doses of up to 960 mg daily for up to 18 months.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)